Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02484547
Recruitment Status : Terminated (Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed)
First Posted : June 29, 2015
Last Update Posted : May 6, 2021
Sponsor:
Information provided by (Responsible Party):
Biogen

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : August 5, 2019
Actual Study Completion Date : August 5, 2019
Certification/Extension First Submitted : August 4, 2020